Urine titin test for Duchenne muscular dystrophy
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This study measures a protein called titin in urine to see if it can help track muscle damage in boys with Duchenne or Becker muscular dystrophy. It also includes healthy boys for comparison.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a boy or young man
- You have a confirmed diagnosis of Duchenne or Becker muscular dystrophy (or you are a healthy child without these conditions)
- You can walk on your own without help
- Your home has electricity and a freezer to store urine samples
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a wrist-worn sensor (Syde) to track arm and hand movement in boys with Duchenne who cannot walk. The goal is to see if the sensor can help doctors monitor changes in arm function over time, which may help guide future care.
This study uses remote technology, like apps or wearable devices, to monitor motor skills and development in boys with Duchenne muscular dystrophy (DMD). It aims to find better ways to measure how the disease progresses over time without requiring frequent clinic visits.
This study looks at how children and teens with Duchenne muscular dystrophy (DMD) or spinal muscular atrophy (SMA) walk, by having them do walking tests while wearing sensors. The goal is to find better ways to track how these diseases progress and how treatments work over time, without needing blood tests or scans.
This study tracks development and health in young boys with Duchenne muscular dystrophy during the first three years of life. It aims to better understand early signs and how the condition progresses, which may help improve care and future treatments.
This study tests whether a new medicine called zeleciment rostudirsen can help ambulatory (walking) males with Duchenne muscular dystrophy (DMD). The medicine is given as an intravenous infusion (through a vein) every 4 weeks and works by helping the body produce a protective muscle protein.
This study looks for signals in blood and other body fluids that may help track Duchenne or Becker muscular dystrophy. It may be helpful for patients by improving how future monitoring tests are developed.
Hear when a new Duchenne Muscular Dystrophy (DMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.